Yoshimasa Inoue

Yoshimasa Inoue

Auto-generated profile, based on publicly available information

Yoshimasa Inoue

Department of Surgery, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8605 Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1994 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
YIYoshimasa Inoue
Yoshimasa Inoue
TNTomoki Nakagawa
Tomoki Nakagawa
HKHiroko Kodama
Hiroko Kodama
HYHitoshi Yamazaki
Hitoshi Yamazaki
KKKenji Kawai
Kenji Kawai
MNMasato Nakamura
Masato Nakamura
Copper-transporting P-type adenosine triphosphatase (ATP7B) is reportedly associated with platinum drug resistance in various solid carcinomas. However, the impact of ATP7B on platinum drug resistance in non-small cell lung cancer (NSCLC) remains unknown. We investigated ATP7B expression in nine human NSCLC xenografts using real-time polymerase chain reaction (PCR) and immunohistochemistry, and examined the relationship between the expression level of ATP7B and in vivo cisplatin (CDDP) sensitivity. ATP7B mRNA expression was significantly correlated with in vivo cisplatin sensitivity [coefficient of determination (R2)=0.949, p=0.005]. ATP7B protein was detected in the nine xenografts. The ATP7B protein expression level was comparable to that of ATP7B mRNA. ATP7B mRNA and protein expression levels in the CDDP-resistant xenografts were significantly higher than those in the CDDP-sensitive xenografts (p=0.0389 and p=0.0357, respectively, Mann-Whitney U test). These results suggest that ATP7B is a CDDP-resistance marker in human NSCLC xenografts in vivo.

21 March 2005 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
YIYoshimasa Inoue
Yoshimasa Inoue
MGMasatoshi Gika
Masatoshi Gika
KNKeijiro Nozawa
Keijiro Nozawa
YIYoshifumi Ikeda
Yoshifumi Ikeda
ITIwao Takanami
Iwao Takanami
Descending necrotizing mediastinitis (DNM) is a rare but often fatal disease. Transcervical mediastinal drainage and transthoracic mediastinal drainage are the most commonly employed drainage methods for treating patients with DNM. It remains controversial as to whether transcervical mediastinal drainage alone would be adequate for the treatment of DNM, which is a life-threatening disease. Between 1996 and 2004, 13 patients with DNM were treated at our department. We performed transcervical mediastinal drainage in 6 patients with localized DNM, in whom the infection remained limited to above the level of the carina. A more aggressive approach, that is, transthoracic mediastinal drainage, was employed in the remaining 7 patients who had extensive DNM, with the infection extending below the carina. The overall mortality rate was 8%. All the 6 patients treated by transcervical drainage survived without major postoperative complications. Six out of the 7 patients treated by transthoracic drainage survived, while one died of pneumonia. Our results suggest that transcervical mediastinal drainage may be adequate for treating patients with localized DNM in whom the infection does not extend beyond the carina, while transthoracic mediastinal drainage must be adopted for patients with more extensive disease.

6 July 2009 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
NANakamura
Nakamura
TCTsuyoshi Chijiwa
Tsuyoshi Chijiwa
YAYoshiyuki Abe
Yoshiyuki Abe
YIYoshimasa Inoue
Yoshimasa Inoue
HMHozumi Matsumoto
Hozumi Matsumoto
MNMasato Nakamura
Masato Nakamura
Thrombospondin (TSP)-2 is known to be an endogenous negative regulator of vascularization in human cancer. However, it is unclear whether TSP-2 expression is related to neovascularization and prognosis in non-small cell lung cancer. In this study, we quantitatively examined the expression of TSP-2 mRNA by real-time reverse transcription-polymerase chain reaction (RT-PCR) in 102 pulmonary adenocarcinomas. All 102 carcinoma specimens expressed TSP-2 mRNA. The expression of TSP-2 mRNA in carcinoma was significantly higher than normal lung tissues (p<0.0001, Kruskal-Wallis test). Sizes of tumors were significantly correlated with TSP-2 gene expression (p=0.0179, Kruskal-Wallis test). The TSP-2 expression levels of the stage II/III pulmonary carcinomas were significantly increased as compared to those of stage I (p=0.0136, Kruskal-Wallis test). Thirty-five patients with high TSP-2 mRNA expression showed poor prognosis in survival (p=0.0139, log-rank test). We examined TSP-2 protein localizations in the pulmonary adenocarcinoma overexpressing TSP-2 mRNA. The TSP-2 localizations were categorized in two patterns: cancerous TSP-2 expression pattern (TSP-2 expression in the cancerous cells) and non-cancerous TSP-2 expression pattern (TSP-2 expression in the stromal lymphoid cells). Pulmonary adenocarcinoma patients with cancerous TSP-2 expression pattern showed good prognosis (p=0.0322; Fisher's probability exact test). Pulmonary adenocarcinoma patients with non-cancerous TSP-2 expression pattern showed poor prognosis (p=0.0220; Fisher's probability exact test). Non-cancerous TSP-2 expressions may reflect secondary reactions in the cancerous stroma. The stromal TSP-2 expression is not enough to suppress growth of pulmonary adenocarcinoma, while the cancerous TSP-2 expression directly inhibits growth of the carcinoma.

13 November 2004 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ITIwao Takanami
Iwao Takanami
YIYoshimasa Inoue
Yoshimasa Inoue
MGMasatoshi Gika
Masatoshi Gika
Background: G-protein inwardly rectifying potassium channel 1 (GIRK1) is thought to play a role in cell proliferation in cancer, and GIRK1 gene expression level may define a more aggressive phenotype. We detected GIRK1 expression in tissue specimens from patients with non-small cell lung cancers (NSCLCs) and assessed their clinical characteristics. Methods: Using reverse transcription-polymerase chain reaction (RT-PCR) analyses, we quantified the expression of GIRK1 in 72 patients with NSCLCs to investigate the relationship between GIRK1 expression and clinicopathologic factors and prognosis. Results: In 72 NSCLC patients, 50 (69%) samples were evaluated as having high GIRK1 gene expression, and 22 (31%) were evaluated as having low GIRK1 gene expression. GIRK1 gene expression was significantly associated with lymph node metastasis, stage (p = 0.0194 for lymph node metastasis; p = 0.0207 for stage). The overall and stage I survival rates for patients with high GIRK1 gene expressed tumors was significantly worse than for those individuals whose tumors had low GIRK1 expression (p = 0.0004 for the overall group; p = 0.0376 for stage I). Conclusions: These data indicate that GIRK1 may contribute to tumor progression and GIRK1 gene expression can serve as a useful prognostic marker in the overall and stage I NSCLCs.

1 February 2005
Verified
Journal Article
Closed access
YIYoshimasa Inoue
Yoshimasa Inoue
MGMasatoshi Gika
Masatoshi Gika
TATomohiro Abiko
Tomohiro Abiko
TOTakahiko Oyama
Takahiko Oyama
YSYuriko Saitoh
Yuriko Saitoh
KKKoichi Kobayashi
Koichi Kobayashi

15 November 2003
Verified
Journal Article
Closed access
NNNoboru Nishiumi
Noboru Nishiumi
YAYoshiyuki Abe
Yoshiyuki Abe
YIYoshimasa Inoue
Yoshimasa Inoue
HHHiroyuki Hatanaka
Hiroyuki Hatanaka
KIKen-Ichi Inada
Ken-Ichi Inada
MNMasato Nakamura
Masato Nakamura